5.58
price down icon9.12%   -0.56
after-market Handel nachbörslich: 5.85 0.27 +4.84%
loading
Schlusskurs vom Vortag:
$6.14
Offen:
$5.89
24-Stunden-Volumen:
1.97M
Relative Volume:
2.03
Marktkapitalisierung:
$446.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.87M
KGV:
-3.0829
EPS:
-1.81
Netto-Cashflow:
$-109.90M
1W Leistung:
-24.29%
1M Leistung:
-30.51%
6M Leistung:
-45.56%
1J Leistung:
-59.42%
1-Tages-Spanne:
Value
$5.53
$5.89
1-Wochen-Bereich:
Value
$5.53
$7.34
52-Wochen-Spanne:
Value
$5.53
$14.67

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Name
Firmenname
Oric Pharmaceuticals Inc
Name
Telefon
(650) 388-5600
Name
Adresse
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
ORIC's Discussions on Twitter

Vergleichen Sie ORIC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ORIC
Oric Pharmaceuticals Inc
5.58 446.76M 0 -119.87M -109.90M -1.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-31 Eingeleitet Wells Fargo Overweight
2024-09-06 Eingeleitet Stifel Buy
2024-02-23 Eingeleitet Cantor Fitzgerald Overweight
2023-09-22 Eingeleitet Wedbush Outperform
2023-03-23 Hochstufung H.C. Wainwright Neutral → Buy
2023-03-21 Hochstufung Guggenheim Neutral → Buy
2023-03-16 Hochstufung Oppenheimer Perform → Outperform
2022-07-18 Fortgesetzt Oppenheimer Perform
2022-04-04 Hochstufung Citigroup Neutral → Buy
2022-03-25 Herabstufung H.C. Wainwright Buy → Neutral
2022-03-22 Herabstufung Citigroup Buy → Neutral
2022-03-22 Herabstufung Guggenheim Buy → Neutral
2022-03-22 Herabstufung Oppenheimer Outperform → Perform
2021-07-06 Hochstufung Citigroup Neutral → Buy
2021-01-25 Herabstufung Citigroup Buy → Neutral
2020-08-13 Eingeleitet Robert W. Baird Outperform
2020-08-06 Hochstufung Citigroup Neutral → Buy
2020-08-03 Eingeleitet H.C. Wainwright Buy
2020-05-19 Eingeleitet Citigroup Neutral
2020-05-19 Eingeleitet Guggenheim Buy
2020-05-19 Eingeleitet JP Morgan Overweight
2020-05-19 Eingeleitet Jefferies Buy
Alle ansehen

Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten

pulisher
04:35 AM

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

04:35 AM
pulisher
04:30 AM

Oncology Pioneer ORIC Sets Stage for 2 Major Healthcare Conference Appearances - Stock Titan

04:30 AM
pulisher
02:03 AM

Analysts Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - Defense World

02:03 AM
pulisher
04:07 AM

Swiss National Bank Has $504,000 Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

04:07 AM
pulisher
Mar 30, 2025

Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - MarketBeat

Mar 30, 2025
pulisher
Mar 28, 2025

Charles Schwab Investment Management Inc. Purchases 7,726 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Mar 28, 2025
pulisher
Mar 26, 2025

ORIC stock touches 52-week low at $6.31 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

ORIC stock touches 52-week low at $6.31 amid market challenges - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

PNC Financial Services Group Inc. Buys 2,520 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Breakthrough: Novel Prostate Cancer Drug Demonstrates Powerful Two-Pronged Attack Strategy - Stock Titan

Mar 25, 2025
pulisher
Mar 25, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9%Time to Sell? - MarketBeat

Mar 25, 2025
pulisher
Mar 24, 2025

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance

Mar 24, 2025
pulisher
Mar 24, 2025

Wedbush Reaffirms Outperform Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat

Mar 24, 2025
pulisher
Mar 23, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9% – Here’s What Happened - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

(ORIC) Investment Report - news.stocktradersdaily.com

Mar 22, 2025
pulisher
Mar 21, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Victory Capital Management Inc. - Defense World

Mar 21, 2025
pulisher
Mar 14, 2025

Oric Pharmaceuticals Expands Equity Incentive Plan for Growth - TipRanks

Mar 14, 2025
pulisher
Mar 12, 2025

(ORIC) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Mar 12, 2025
pulisher
Mar 07, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Mar 07, 2025
pulisher
Mar 07, 2025

ORIC's Latest Employee Stock Grants: Key Details on Compensation Package - StockTitan

Mar 07, 2025
pulisher
Mar 07, 2025

Rhumbline Advisers Purchases 4,072 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Mar 06, 2025
pulisher
Mar 06, 2025

ORIC Pharmaceuticals (ORIC) Projected to Post Earnings on Monday - MarketBeat

Mar 06, 2025
pulisher
Mar 05, 2025

ORIC Pharmaceuticals Reports Progress in Cancer Trials - TipRanks

Mar 05, 2025
pulisher
Mar 04, 2025

Wedbush Expects Increased Earnings for ORIC Pharmaceuticals - MarketBeat

Mar 04, 2025
pulisher
Mar 03, 2025

ORIC Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% After Analyst Upgrade - MarketBeat

Mar 02, 2025
pulisher
Mar 01, 2025

(ORIC) Investment Analysis and Advice - news.stocktradersdaily.com

Mar 01, 2025
pulisher
Mar 01, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 - Defense World

Mar 01, 2025
pulisher
Mar 01, 2025

ORIC Pharmaceuticals’ (ORIC) Buy Rating Reiterated at Guggenheim - Defense World

Mar 01, 2025
pulisher
Mar 01, 2025

Wedbush Equities Analysts Lift Earnings Estimates for ORIC - Defense World

Mar 01, 2025
pulisher
Feb 28, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% on Analyst Upgrade - Defense World

Feb 28, 2025
pulisher
Feb 26, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 at JPMorgan Chase & Co. - MarketBeat

Feb 26, 2025
pulisher
Feb 26, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Receives "Buy" Rating from Guggenheim - MarketBeat

Feb 26, 2025
pulisher
Feb 25, 2025

Oric Pharmaceuticals announces clinical development plans for ORIC-944, ORIC-114 - TipRanks

Feb 25, 2025
pulisher
Feb 25, 2025

ORIC® Pharmaceuticals Announces Focused Registrational - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

Can ORIC Pharmaceuticals' Extended Cash Runway Fuel Success in Cancer Drug Development? - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Wedbush Reduces Earnings Estimates for ORIC Pharmaceuticals - MarketBeat

Feb 25, 2025
pulisher
Feb 24, 2025

HC Wainwright Reaffirms "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat

Feb 24, 2025
pulisher
Feb 23, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up Following Earnings Beat - MarketBeat

Feb 23, 2025

Finanzdaten der Oric Pharmaceuticals Inc-Aktie (ORIC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Kapitalisierung:     |  Volumen (24h):